You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company plans to offer about 3.2 million shares of its common stock at $2.80 per share.
CombiMatrix expects to receive net proceeds of $4.75 million from the offering, which it plans to use for general corporate purposes.
The firm closed its offering of 2,475,000 shares of stock at a price of $3.75 per share. It plans to use the proceeds to fund colorectal cancer clinical trials.
The company closed on the public offering of more than 5 million shares of its common stock at $4.50 per share.
The company is offering up to 8 million shares of its common stock and warrants to purchase up to 8 million shares of its stock.
The firm said in an SEC document that it plans to offer up to $11.5 million in its common shares and up to $11.5 million in common stock issuable upon the exercise of warrants.
The firm, which was previously listed on the over-the-counter market, anticipates $8.5 million in net proceeds from the offering.
The company plans to offer 4.4 million shares of its common stock in the offering.
The firm's president and CEO said there are no imminent financing plans.
The company, which went public about a year ago, plans to offer about 6.3 million shares of its common stock.
Nature News reports that genomics is being applied to trace and try to prevent additional COVID-19 waves.
Rady's Children Hospital and San Diego County are teaming up to test pediatric patients and their families for COVID-19 to gauge the spread of the virus locally, according to the San Diego Union-Tribune.
Wildlife managers aim to boost the genetic diversity of Mexican gray wolves by placing captive-born foster pups into packs with similarly aged wild pups, the Mercury News reports.
In Science this week: Genetic Probability tool identifies likely diagnoses in 45 percent of inflammatory arthritis cases, and more.